In Q2:2021, GLAXOSMITH witnessed a turnaround in revenue (+17.82%YoY) buoyed by a 55.37%
increase in revenue from its consumer healthcare unit and a 4.69% increase from the
pharmaceutical business unit. However, the top-line contraction witnessed in the first quarter took
the spotlight, suppressing H1:2021 revenue by 5.46% YoY to NGN9.86bn from NGN10.43bn in
H1:2020.
Kindly use the link below to download the full report.
